期刊文献+

miR-30a-5p在肾癌中的表达分析及临床意义研究 被引量:4

Research on the expression of miR-30a-5p and its clinical significance in renal tumor
原文传递
导出
摘要 目的:本研究通过检测32对肾细胞癌组织标本及相应癌旁正常组织标本中miR-30a-5p的表达水平,然后分析miR-30a-5p的表达量与患者临床特征之间的关系,为更深一步研究miR-30a-5p在肾细胞癌的发病机制的作用和功能的研究打下基础。方法:收集32对经手术切除的肾细胞癌及相应的癌旁组织标本,提取标本的总RNA,经反转录获得cDNA,并通过实时荧光定量PCR(qRT-PCR)方法检测miR-30a-5p的表达水平,利用统计学方法分析其表达量与患者临床特征之间有无相关性。结果:32对组织标本中有27例(84.38%)肾细胞癌组织的miR-30a-5p表达水平下降(P<0.01),且统计学分析表明其下降和患者的年龄、性别、组织学分型及临床分期等临床特征无明显相关性(P>0.05)。结论:miR-30a-5p在肾癌组织中表达明显下调,提示其可能与肾癌的发生发展有一定的相关性。 Objective:To examine the expression levels of miR-30a-5p in 32 RCC tissues and paired normal tissues,and then explore the relationship between miR-30a-5p expression and clinical characteristics of patients for further study of the function of miR-30a-5p in RCC.Method:Total RNA that extracted from 32 paired tissues resected from nephrectomy was used to get cDNA by performing reverse transcription.Quantitative real-time PCR(qRT-PCR)was used to examine the expression level and statistic analysis was used to explore the relationship between clinical characteristic and expression of miR-30a-5p.Result:Expression of miR-30a-5p down-regulated in 27cases(84.38%)(P 0.01).No relationships could be found between the expression of miR-30a-5p and patients' age,gender,histological classification or clinical stage(P 0.05).Conclusion:Expression of miR-30a-5p downregulated in RCC tissues,which may demonstate the correlation between its expression and the initiation and development of RCC.
出处 《临床泌尿外科杂志》 2016年第3期215-219,共5页 Journal of Clinical Urology
基金 国家自然科学基金(编号81101922) 广东省医学科研基金(编号A2012584 A2013606) 2013年深圳市科技研发资金知识创新计划基础研究项目(编号JCYJ20130402114702124) 广东省重点医学专科经费
关键词 microRAN miR-30a-5p 肾细胞癌 肿瘤分期 microRAN miR-30a-5p renal cell carcinoma tumor stage
  • 相关文献

参考文献32

  • 1Cairns P.Renal cell carcinoma[J].Cancer Biomark,2010,9(1-6):461-473".
  • 2Kroeze S G,Bijenhof A M,Bosch J L,et al.Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma[J].Cancer Biomark,2010,7(6):261-268.
  • 3Yu Z H,Zhang Q,Wang Y D,et al.Overexpression of cyclooxygenase-1correlates with poor prognosis in renal cell carcinoma[J].Asian Pac J Cancer Prev,2013,14(6):3729-3734.
  • 4Hadoux J,Vignot S,De La Motte Rouge T.Renal cell carcinoma:focus on safety and efficacy of temsirolimus[J].Clinical Medicine Insights Oncology,2010,4:143".
  • 5McLaughlin J K,Lipworth L,Tarone R E.Epidemiologic aspects of renal cell carcinoma[J].Semin Oncol,2006,33(5):527-533.
  • 6Janzen N K,Kim H L,Figlin R A,et al.Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease[J].Urol Clin North Am,2003,30(4):843-852.
  • 7Cimmino A,Calin G A,Fabbri M,et al.miR-15and miR-16induce apoptosis by targeting BCL2[J].Proc Natl Acad Sci U S A,2005,102(39):13944-13949.
  • 8Bouyssou J M,Manier S,Huynh D,et al.Regulation of microRNAs in cancer metastasis[J].Biochim Biophys Acta,2014,1845(2):255-265.
  • 9Xi Y.MicroRNA:A New Player for Cancer Chemoprevention[J].J Integr Oncol,2013,2(1):pii:105.
  • 10Ichimi T,Enokida H,Okuno Y,et al.Identification of novel microRNA targets based on microRNA signatures in bladder cancer[J].Int J Cancer,2009,125(2):345-352.

同被引文献21

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部